← All trials
NCT05874622
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 12, 2023
- Primary completion
- Oct 18, 2023
- Completion date
- Oct 25, 2023
- First posted
- May 25, 2023
- Last posted
- Nov 3, 2023
- Enrollment
- 30
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu vcare pharmaceutical technology co., LTDLead sponsor
- Jinlin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.